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The human immunodeficiency virus type 1 (HIV-1) transactivator Tat protein is essential for efficient viral gene expression
and virus replication. The Tat core domain, a stretch of 12 amino acids between the cysteine-rich and the basic domain,
is conserved in all HIV isolates and required for interaction with a number of cellular transcriptional regulatory proteins.
Here we demonstrate that soluble peptide analogs of the Tat core domain (amino acid 36–50) are able to effectively block
LTR transactivation. In transfection experiments, Tat core peptide analogs containing amino acid substitutions at position
41 and 44 inhibited Tat transactivation of an HIV-1 LTR-CAT reporter construct up to 80-fold. In contrast, inhibition of other
promoters such as HTLV-I and CMV was approximately 2-fold. Tat peptide analog 36–50 (41/44) inhibited HIV virus
replication by 85% in latently infected U1 cells induced with Tat. Furthermore, U1 cells treated with the Tat peptide 36–50
(41/44) analog showed markedly delayed virus transmission when cocultivated with parental U937 cells. Interestingly, while
both short and long peptide analogs (amino acids 36–50 vs 36–72) inhibited Tat transactivation in transient assays, the
short peptides were more effective inhibitors of virus replication in U1 cells. The Tat peptide analog did not decrease
expression of cellular genes including b-actin, GAPDH, and histone H2B. q 1997 Academic Press
INTRODUCTION Tat peptides spanning amino acids 37–72 could inhibit
Tat transactivation of the HIV LTR. Peptide inhibition was
Human immunodeficiency virus type 1 (HIV-1) encodes dependent upon amino acid substititution at positions
a potent viral transactivator, Tat. Subsequent to the inte- 41, 46, or 47 of the Tat protein. Subsequent studies re-
gration of viral DNA, a major function of Tat is to transacti- ported the characterization of a HIV-2 Tat transdominant
vate the viral long terminal repeat (LTR) to regulate the protein, which inhibited Tat transactivation of both HIV-
production of viral mRNA (Arya et al., 1985; Sadaie et al., 1 and HIV-2 promoters (Echetebu et al., 1994). The inhibi-
1988). Tat has been reported to function at both transcrip- tory effect of Tat proteins has also been shown where
tion initiation and elongation (Kashanchi et al., 1994; EIAV Tat alone or chimeric EIAV/HIV-1 Tat proteins inhib-
Xhou and Sharp, 1995; Chiang and Roeder, 1995). The ited HIV-1 Tat-mediated transactivation in a cell-type-de-
Tat core domain, a stretch of 12 amino acids between the pendent fashion (Rice et al., 1993).
cysteine-rich and the basic domain which is conserved in In this study, we extend these earlier observations
all HIV isolates, is required for interaction with a number by demonstrating that soluble Tat core domain peptide
of cellular transcriptional regulatory proteins. We have analogs with substitutions at amino acids 41 and 44 ef-
previously demonstrated that mutations within the core fectively block Tat transactivation and, importantly, virus
domain abolished the interaction of Tat with human TATA replication. While short and long peptide analogs (amino
binding protein (TBP), a subunit of the basal transcription acids 36–50 vs 36–72) inhibited Tat transactivation in
factor TFIID (Kashanchi et al., 1994). In addition to TBP, transient assays, the short peptides were more effective
the core domain has been implicated in binding of other inhibitors of virus replication in U1 cells. The Tat peptides
cellular transcription factors including Tat-associated are able to downregulate viral mRNA synthesis without
protein (TAP) (Yu et al., 1995), Tat-associated kinase any inhibitory effect on cellular mRNA synthesis. The
(TAK) (Herrmann and Rice, 1995), and Sp1 (Jeang et al., use of inhibitory peptides, or synthetic compounds using
1993). peptide mimetics, may be developed as an inhibitor of
Pearson et al. (1990) have previously shown that a HIV virus replication.
truncated form of Tat, containing the wild-type core and a
truncated basic domain, inhibited HIV-1Tat-induced gene METHODS
expression. Similarly, Green et al. (1989) reported that
Electroporation of cells
Cells were electroporated as described previously (Ka-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (301) 496-4951. E-mail: bradyj@dce41.nci.nih.gov. shanchi et al., 1992). CEM CD4/ lymphocytes (12D7) and
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U1 (A. Fauci, Laboratory of Immunoregulation/NIAID.NIH) Green, U. Mass. Medical Center), Gal4-Tat, and a CMV-
TBP expression plasmid (Southgate and Green, 1991;and HeLa cells were kept at a density of 0.5 to 0.8 1 106
cells/ml with media added daily. Typically, 5 1 106 cells Horikoshi et al., 1995). Peptides were added at the time
of electroporation. Following electroporation, cells werewere electroporated with purified peptides, Tat protein,
and/or 5 mg of a reporter plasmid. Synthetic Tat peptides plated in complete media, harvested at 48 hr, and CAT
assays performed. The Gal4-TATA//TAR0 plasmid con-were purified by HPLC to 95% purity (Peptide Technolo-
gies Corp., Gaithersburg, MD). All peptides were ana- tains six Gal4 binding sites, followed by the HIV se-
quence from 031 to /25. This construct contains no Sp1lyzed for purity on a 4–20% gradient SDS/PAGE followed
by silver staining. Recombinant Tat protein was purified sites or a TAR element.
by reverse-phase HPLC and tested for functional activity
in an in vitro transcription assay and in vivo electropora- Tat peptide amino acid sequences
tion into CEM cells (Kashanchi et al., 1992; Bohan et al.,
The amino acid sequences for the Tat peptides are:1992). Tat peptide, Tat protein, and the reporter HIV LTR-
Tat 36-50: V-C-F-T-T-K-A-L-G-I-S-Y-G-R-K. Tat 36-50 (41):CAT were mixed with cells and electroporated using a
V-C-F-T-T-A-A-L-G-I-S-Y-G-R-K. Tat 36-50 (44): V-C-F-T-T-cell porater apparatus (Gibco/BRL, Gaithersburg, MD).
K-A-L-S-I-S-Y-G-R-K. Tat 36-50 (46): V-C-F-T-T-K-A-L-G-I-Cell mixtures were electroporated at 800 mF, 230 V, in
A-Y-G-R-K. Tat 36-50 (47): V-C-F-T-T-K-A-L-G-I-S-A-G-R-K.RPMI 1640 media without fetal calf serum. Following
Tat 36-50 (41/44): V-C-F-T-T-A-A-L-S-I-S-Y-G-R-K. Tat 36-electroporation, cells were plated in 10 ml of complete
50 (41/46): V-C-F-T-T-A-A-L-G-I-A-Y-G-R-K. Tat 36-50 (41/media and samples collected 48 hr later for CAT assay,
47): V-C-F-T-T-A-A-L-G-I-S-A-G-R-K.p24 Gag antigen capture assay, or Northern blot analysis.
We have consistantly observed a 40–45% efficiency of
RESULTStransfection when using the electroporation method (data
not shown). Samples receiving rTNF-a (R & D Systems, Suppression of transcriptional activation using Tat
Minneapolis, MN) after electroporation were collected peptides
48 hr posttreatment for p24 Gag antigen capture assay.
Initial studies focused on the analysis of a series of
Cocultivation of U1 cells Tat peptide analogs, containing various amino acid sub-
stitutions, for their ability to inhibit Tat transactivation ofTransfected U1 cells (5 1 106) were cocultivated with
the U937 cells 48 hr after transfection. The cocultivation the HIV-1 promoter. CEM lymphocytes, grown to early-
to mid-log phase, were electroporated with the Tat pro-assay was initially tested using a 1:1, 1:5, or 1:25 ratio
of infected to uninfected cells. A 1:5 cocultivation was tein, Tat peptide, and the HIV-1 LTR-CAT reporter (Kah-
sanchi et al., 1992). In these and subsequent experi-determined to be the optimal ratio in obtaining the high-
est viral production within a 2-week period. Cells were ments, we have used purified Tat protein, as opposed
to an expression vector containing Tat gene, since Tatcocultivated in a total of 4 ml for a period of 2 weeks.
After the first week, 2 ml of cell growth media was re- peptide analogs could potentially alter the promoter ac-
tivity of the Tat expressing plasmid. Tat protein increasedmoved and 2 ml of fresh media added. Both U937 and
CEM cells were seeded at a density of 0.5 1 106 cells HIV-1 LTR-directed gene expression from 2.1 to 95% (45-
fold) (Fig. 1A, lanes 1 and 2). When wild-type 36–50 pep-per culture dish prior to the cocultivation experiment.
tide was included in the transfection mix, no apparent
Northern blot analysis drop in transcription activity was observed (Fig. 1A, lane
3). This lack of competition between wild-type Tat proteinU1 or HLM1 (Tat0 HIV-1 proviral clone) (Sadaie and
Hager, 1994) cells were transfected with either Tat pro- and wild-type Tat peptide was also apparent when using
each of the four single Tat peptide analogs, i.e., Tat 41,tein or Tat protein in combination with peptides and col-
lected 48 hr later. Total RNA was extracted using the 44, 46, and 47 (Fig. 1A, lanes 3–7). In contrast, the mini-
mal Tat peptide analogs with double amino acid substitu-Trizol reagent (Gibco/BRL). RNA concentration was mea-
sured and equivalent amounts of RNA (5 mg) were loaded tions showed varying degrees of ability to inhibit HIV
transactivation. Most notably, peptide analog 41/44on a formaldehyde–agarose gel. The RNA was blotted
onto nitrocellulose and hybridized with a randomly showed suppression of Tat transactivation from 95.7 to
1.1% (Fig. 1A, lane 8). This inhibitory activity was lessprimed 32P-labeled HIV-1 proviral genome BH10 (Lofs-
trand, Inc.), histone H2b, b-actin, or GAPDH probe (Oncor evident with peptide analogs 41/46 or 41/47 (Fig. 1A,
lanes 9 and 10). We conclude that in transient transfec-Science, Inc.). Blots were washed, exposed, and quanti-
tated using a PhosphorImager (Molecular Dynamics). tion assays, Tat peptide analogs were effective competi-
tors for wild-type Tat protein in downregulating Tat-acti-
Transfection of Gal4 constructs vated transcription. In contrast to earlier studies by Green
et al. (1989), but consistent with results of Frankel etCEM cells were transfected with combinations of Gal4-
TATA//TAR0 reporter plasmid (a generous gift from M. al. (1989), we do not see any significant transactivating
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FIG. 1. Electroporation of HIV LTR-CAT with Tat protein and Tat core domain peptides. (A) HIV LTR-CAT (5 mg) was electroporated into CEM
cells with 1 mg of purified Tat protein and 5 mg of core peptide from position 36–50. Cells were harvested 48 hr posttransfection and CAT assays
were performed with 30 mg of total protein. Lanes 2–10 contain Tat either alone or with various core peptide analogs. Sample 1 represents the
basal activity in CEM cells. Values represent the percentage of conversion of the [14C]chloramphenicol substrate in the CAT assay. The experiment
is a representative from three independent assays. (B) A minimal HIV promoter (031//25) with Gal4 binding sites (Gal4-TATA//TAR0) was used
as the reporter construct. Gal4-TATA//TAR0 (5 mg), Gal4-Tat (5 mg), hTBP expression vector, and Tat peptides were electroporated into CEM cells
as indicated. ‘‘Vector’’ indicates the backbone vector for the hTBP construct. (C) Similar electroporation as A, but reporter genes used were HTLV-
I LTR (pU3R CAT, 5 mg) or pCMV-CAT (5 mg), containing the CMV promoter. Lanes 1 and 6 represent basal activity of pU3R CAT or pCMV-CAT,
respectively. Lanes 2, 3, 7, and 8 contain reporter plasmid with either 1 or 5 mg of core peptide analog 36–50 (41/44). Lane 4 contains the HTLV-
I Tax1 protein (1 mg) and lane 5 contains Tax1 protein with 5 mg of peptide 36–50 (41/44).
activity with either the 36–50 or 36–72 peptides alone of the promoter. The ability of Gal4-Tat to activate this
promoter is dependent upon the presence of exoge-(data not shown).
Further evidence that the peptides inhibit Tat transacti- nously added TBP (Fig. 1B, lanes 2–4). This result is in
agreement with published data which demonstrate thatvation was obtained using a minimal HIV-1 promoter
(031 to /21) with Gal4 binding sites located upstream TBP or TBP-containing complexes stimulate Tat trans-
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FIG. 2. Titration of Tat protein and TNF-a on U1 HIV-1 monocytes. (A) U1 cells at 5 1 106 per sample were electroporated with varying amounts
of Tat protein (lanes 2–6) and supernatants were collected 48 hr later for p24 antigen capture assay. Tat protein (2.5 mg) was electroporated with
either 5 mg of peptide 36–50 or analog 36–50 (41/44) (lanes 7 and 8). (B) Comparison of the inhibitory activities of long and short peptide analogs
on viral replication in U1 cells. Lane 1 represents basal p24 expression level of U1 cells. Lanes 2–6 each received 2.5 mg Tat protein in the
presence of peptide 36–72 (lane 3), peptide 36–72 41/44 (lane 4), or peptide 36–50 (lane 5), peptide 36–50 41/44 (lane 6). Lanes 7, 8, 9, and 10
received peptide 36–72, 36–72 41/44, 36–50 or 36–50 41/44, respectively. Supernatants were harvested 48 hr posttransfection for HIV-1 p24
antigen capture assay.
activation from the HIV-1 promoter (Xhou and Sharp, mal inhibition was observed using the peptide analog
41/44. For example, basal transcription of the HTLV-I1995; Veschambre et al., 1995). We next examined if the
peptides were capable of downregulating the TBP/Tat- promoter decreased from 19 to 16.4% using 5 mg of the
peptide analog 41/44 (Fig. 1C, lanes 1 and 3). Similarly,activated transcription by electroporating CEM T-cells
with either wild-type or peptide 41/44. The 41/44 peptide Tat peptide analog 41/44 decreased Tax1-transactivated
transcription approximately twofold (49.2 to 22.8%; Fig.inhibited TBP/Tat-activated transcription approximately
10-fold (Fig. 1B, lanes 3, 6, and 7). 1C, lanes 4 and 5). In other control experiments, tran-
scription from the CMV promoter was decreased fromIn a separate experiment, the inhibitory activity of the
short peptide 36–50 analogs was compared to longer 17.8 to 6.7% in the presence of 5 mg of Tat peptide analog
41/44 (Fig. 1C, lanes 6–8). These results suggest thatderivatives containing amino acids 36–72. Both short
and long peptide analogs containing double amino acid the Tat peptide analog 41/44 has a preferential effect on
HIV-1 transactivation.substitutions were more efficient inhibitors than those
peptide analogs containing single amino acid substitu- Inhibition of viral replication by Tat peptide analog in
tions (data not shown). Interestingly, we demonstrate be- latently infected cells induced by Tat
low that the short peptide analogs are more efficient at
The ability of the Tat peptide analog 41/44 to inhibitinhibiting Tat-induced HIV-1 virus replication.
HIV virus replication was tested in U1 cells. These cells
contain two integrated copies of the wild-type HIV viralEffect of Tat peptide analogs on other promoters
genome, but require exogenous Tat or cytokines to in-
duce production of viral particles. Maximum virus wasIt was of interest to determine if the peptides inhibited
transcription from other polymerase II promoters. We induced when 2.5 to 5 mg of Tat protein was added to
the cell culture (Fig. 2A, lanes 1–6). Next, Tat proteinhave tested seven promoters, including HTLV-I, CMV,
PTHrP, IgH, RAS, RSV, and SIV. Each promoter, cloned was electroporated along with Tat peptide or analogs.
In comparison to the wild-type peptide, Tat peptide ana-upstream of the CAT reporter gene, was cotransfected
with the Tat peptides under identical conditions. Each of log 41/44 inhibited Tat-induced virus production in U1
cells by approximately 85% (Fig. 2A, lanes 7 and 8).the independent experiments gave similar results; mini-
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In a comparable experiment, we have tested the ability did not induce viral replication (data not shown). In an
independent analysis, we have also examined a coculti-of Tat peptide analogs 36–72 to inhibit virus replication
in U1 cells. The addition of Tat protein to the U1 cells vation of U1 with CEM CD4/ T-lymphocytes and ob-
served a similar result with the peptide analog 41/44induced HIV-1 viral replication (Fig. 2B, lanes 1 and 2).
The addition of peptide 36–72 failed to inhibit virus repli- after 14 days of cocultivation (data not shown).
Importantly, no toxic effect of the peptides was ob-cation (Fig. 2B, lane 3). Peptide analog 36–72 (41/44)
inhibited virus replication by approximately 30% (Fig. 2B, served in the cell culture assays. Microscopic inspection
and trypan blue staining revealed no significant differ-lane 4). Peptide analog 36–50 41/44 inhibited replication
by approximately 75% (Fig. 2B, lane 6). We conclude from ence between control and experimental cultures (data
not shown). As a further control, the effect of the peptidesthese studies that the short peptide analogs are more
effective inhibitors of HIV-1 virus replication in U1 cells. were also monitored at the mRNA expression level using
Northern blots. Cellular RNAs, including b-actin, histoneMoreover, the double amino acid analogs are more effec-
tive inhibitors of transcription and virus replication than H2b, and GAPDH, were monitored in cells treated with
Tat and peptide analogs. No significant decreases in thesingle amino acid analogs. In contrast to earlier studies
of Green et al. (1989), peptides alone, in the absence of levels of cellular RNAs were detected (Fig. 4). Consistent
with the results of the p24 virus replication assays, in U1Tat protein, did not induce viral replication in U1 cells
(Fig. 2B, lanes 7–10). cells treated with Tat and the 41/44 Tat peptide analog
a decrease in the level of HIV-1 viral mRNA was detectedThe cytokine TNF-a is also able to induce virus pro-
duction in U1 cells (Chowdhury et al., 1993). In our assay (Fig. 4A, top, lanes 3 and 5). In contrast, no change in
the expression of the cellular GAPDH gene was observedconditions, the addition of 500 units of TNF-a to the
growth media is sufficient to induce maximum virus pro- (Fig. 4A, middle).
The results presented in Fig. 4B represent a separateduction, as judged by a HIV-1 p24 Gag antigen capture
assay. Upon transfection of Tat peptide analog along experiment, in which Tat peptide analog 36–72 (41/44)
was introduced into HeLa HLM1 cells. These cells con-with addition of TNF-a, virus production was decreased
by approximately 63% (data not shown). Thus, Tat peptide tain a triple termination codon in the Tat gene, but other-
wise contain wild-type HIV-1 sequence. Similar to theanalogs are also able to inhibit cytokine-induced HIV-1
replication. results observed in the U1 cells, a significant decrease
in viral mRNA (90% of full-length mRNA) was observed
in the cells treated with the Tat peptide (Fig. 4B, top,Effect of Tat analog peptides in cocultivation assay
lanes 3–6). In contrast, no significant change in the levels
of H2b, b-actin, or GAPDH mRNA were detected (Fig.Approximately one infectious HIV virus particle corre-
sponds to 50,000 to 100,000 physical particles (Dimitrov 4B, middle). The increased level of b-actin mRNA in the
Tat-treated cells was observed in several experimentsand Martin, 1995). Thus, while p24 levels were dimished
in the initial infected cell supernatants, it was of interest and is under investigation. These results suggest that
the Tat peptide analogs selectively inhibit HIV-1 virusto determine whether the level of infectious virus parti-
cles produced in the presence of Tat peptide analog mRNA synthesis and are not toxic to these cells.
41/44 was sufficient to initiate a second round of virus
replication. To address this question, we utilized assays DISCUSSION
in which the induced U1 cells were cocultivated with the
parental U937 monocyte cell line. We initially titrated U1/ The present study was designed to analyze the poten-
tial use of targeted Tat core peptides (amino acids 36–U937 at 1:1, 1:5, and 1:25 ratios and observed that 1:5
cocultivations were optimal for virus replication in the 50) to inhibit HIV-1 transcription and virus replication.
This domain of Tat has been reported to interact withcourse of the 2-week assay (data not shown). Cells were
electroporated with either wild-type or peptide analog several cellular proteins including TFIID (Kashanchi et
al., 1994), Tat-associated protein (TAP) (Yu et al., 1995),41/44, along with Tat protein. The p24 antigen capture
assays were performed 48 hr posttransfection on an ali- Tat-associated kinase (TAK) (Herrmann and Rice, 1995),
and Sp1 (Jeang et al., 1993). Each of these proteins hasquot of the infected culture; the remaining cells were
used for cocultivation assays. The results of this experi- the potential to play an important role in HIV replication.
Interaction of Tat with TFIID stabilizes the formation ofment demonstrated that the initial inhibition of HIV-1 virus
production by the peptide analog 41/44 (Fig. 3A, lanes 2 the HIV TFIID/TFIIA preinitiation complex, a rate limiting
step in transcription initiation. TAP, identified by Tat pep-and 4) was sufficient to inhibit subsequent rounds of
virus replication in the cocultivation assay (Fig. 3B). Fol- tide-affinity chromatography contains a strong transcrip-
tion activation domain and interacts with the basal tran-lowing 7 days of cocultivation, virus production was de-
creased by 85%. Consistent with the transfection assay scription factor TFIIB. TAK was identified using an in vitro
kinase assay for Tat-asociated proteins. A substrate ofdata, the wild-type core peptide did not inhibit HIV virus
replication. Peptides alone, in the absence of Tat protein, TAK is the CTD of polymerase II, the phosphorylation of
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FIG. 3. Cocultivation of U1 with U937 cells. (A) U1 cells were electroporated with 2.5 mg of Tat (lanes 2–4) along with wild-type peptide (lane 3)
or peptide analog 41/44 (lane 4). Cells were harvested 48 hr later and used for p24 antigen capture or cocultivation assay. (B) A 1:5 ratio of U1/
U937 was used for the cocultivation experiment in a total of 4 ml media (see Materials and Methods). Aliquots (400 ml) were collected at Days 2,
3, 7, and 14 for p24 antigen capture assay.
which has been reported to trigger the transition from reported that Tat regulates the binding of RNA polymer-
ase II to the TAR RNA (Wu-Baer et al., 1995). Potentialinitiation to elongation. Sp1 has three binding sites up-
stream of the HIV initiation site and plays a major role direct interaction between Tat and polymerase II may
regulate the transition from transcription initiation toin enhancing transcription efficiency. It has also been
FIG. 4. Northern blot analysis of U1 and HLM1 cells following transfection of Tat and Tat analog peptides. (A) RNA samples were collected using
the Trizol method and quantitated by spectophotometer. RNA samples were electrophoresed on a formaldehyde–agarose gel, transferred, and
hybridized with either a whole HIV-1 (BH10)-labeled probe or an anti-sense GAPDH oligonucleotide. Lane 1 represents no protein added, lane 2
contained 2.5 mg of Tat41 purified protein, lanes 3–5 all contained 2.5 mg of Tat protein alone (lane 3), with Tat peptide 36–50 (lane 4), or with
36–50 (41/44) analog (lane 5). Bottom panel represents an ethidium bromide staining of the agarose gel prior to transfer. (B) HLM1 (HeLa/Tat0)
cells were electroporated with Tat plasmid (lane 2) or Tat plasmid with increasing concentrations of a Tat peptide analog 36–72 41/44 (0.1, 0.5,
2.5, and 5.0 mg; lanes 3–6). Samples were collected 48 hr after electroporation and used for Northern blot analysis.
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elongation, a limiting step in HIV transcription. Thus, Tat result suggest that treatment of the U1 cells with the Tat
peptide analog has reduced virus production below thepeptides have the potential to regulate many steps of
transcription initiation and elongation. In addition, it has threshold required to sustain continued virus replication.
In independent cocultivation assays, we have also ob-been recently reported that Tat plays an additional role
in HIV virus infectivity/cytopathicity (Huang et al., 1994). served a similar pattern of inhibition when using CEM
(12D7 CD4/ T-lymphocyte) cells as the source of unin-It is possible that Tat peptides could also block this im-
portant function of the Tat protein. fected cells (data not shown). Future studies will deter-
mine the effectiveness of Tat peptides against differentPeptide analogs containing amino acid substitutions at
residues 41/44, 41/46, and 41/47 demonstrated variable viral clades and various cell types.
Recent reports demonstrate the potential use of pep-levels of transdominant repressor activity. Of significant
interest, peptide analog 41/44 effectively inhibits Tat tides to mimic the activity of large polypeptide hormones
(Wrighton et al., 1996; Livnah et al., 1996). Using phagefunction in either transient transfection assays or in virus
replication assays. Previous studies using functional, display, a 20-amino-acid peptide that binds to and acti-
vates the receptor for eythropoietin, a 165-amino-acidlonger analogs of Tat encompassing the core and basic
domains (aa 36–72) have reported that single or double protein, has been identified. Moreover, analysis of the
structure of the peptide–receptor complex has revealedamino acid substitutions (41, Ala; 46, Ala; 47, Ala; 46, Ala
plus 47, Ala) result in transdominant inhibition of Tat at the atomic level how the peptide dimerizes the EPO
receptor. These reports represent a significant advancefunction. The present studies thus identify a novel double
mutation within the minimal Tat core domain that com- in peptide mimetics and demonstrate that a peptide can,
in fact, mimic the activity of a larger protein. Our descrip-petes for wild-type Tat function. Because of the overlap-
ping functions of the Tat core domain, through interaction tion of a Tat peptide analog which inhibits Tat transacti-
vation and HIV virus replication has strong potential. Thewith several transcriptional regulatory proteins, we can-
not yet distinguish which protein–protein interaction is peptide could be utilized to analyze the physical change
induced in Tat binding proteins. Moreover, the peptideinhibited by the peptide (Yu et al., 1995; Herrmann and
Rice, 1995; Jeang et al., 1993; Huang et al., 1994). Studies analog could serve as a lead compound for synthesis of
organic mimetic compounds.to identify potential cellular targets of the Tat peptide
analogs are in progress.
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